EUVIMEDEUVIMED entdecken
Crossref

Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective

Francisco Javier Melgosa Ramos iD, Javier Mataix, Sergio Santos Alarcón, Jose María Ortiz Salvador, Gemma Martín Ezquerra, Antonio Martorell iD

International Journal of Dermatology · 21.05.2026

DOI: 10.1111/ijd.70491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 21.05.2026. Verfasst von Francisco Javier Melgosa Ramos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bimekizumab shows high efficacy in moderate‐to‐severe hidradenitis suppurativa, achieving deep clinical responses and improving structural lesions such as draining tunnels. However, mucocutaneous candidiasis is the most characteristic adverse event due to IL‐17 pathway inhibition, although it is usually mild and manageable. Based on clinical experience, a proactive, risk‐adapted approach including targeted antifungal strategies may improve tolerability. This perspective supports shifting from reactive to preventive management to optimize long‐term treatment persistence.

Schlagwörter

Stichwörter der Autor:innen

bimekizumabcandidiasishidradenitis suppurativa

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain.
  • Department of Dermatology, Marina Baixa Hospital, Alicante, Spain.
  • Department of Dermatology, Hospital Virgen de los Lirios, Alicante, Spain.
  • Department of Dermatology, Hospital General Universitario, Valencia, Spain.
  • Department of Dermatology, Hospital del Mar, Barcelona, Spain.
  • Department of Dermatology, Hospital de Manises, Valencia, Spain.

ORCID-Profile: Francisco Javier Melgosa Ramos, Antonio Martorell

Zitieren

APA

Melgosa Ramos, F. J., Mataix, J., Santos Alarcón, S., Ortiz Salvador, J. M., Martín Ezquerra, G., & Martorell, A. (2026). Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective. International Journal of Dermatology. https://doi.org/10.1111/ijd.70491

Vancouver

Melgosa Ramos FJ, Mataix J, Santos Alarcón S, Ortiz Salvador JM, Martín Ezquerra G, Martorell A. Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective. International Journal of Dermatology. 2026. doi:10.1111/ijd.70491

BibTeX
@article{MelgosaRamos2026,
  author = {Melgosa Ramos, Francisco Javier and Mataix, Javier and Santos Alarcón, Sergio and Ortiz Salvador, Jose María and Martín Ezquerra, Gemma and Martorell, Antonio},
  title = {Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70491}
}
Kostenlos starten →